Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine
kinases, and it has been approved as a third-line therapy for patients with advanced non …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

Background Anlotinib (AL3818) is a novel multi-target angioenesis TKI targeting the VEGFR,
FGFR, PDGFR and c-Kit. In the ALTER0303 trial, Anlotinib as third-line treatment …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Abstract Background On May 8, 2018, the China National Medical Products Administration
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …

Objective: This study aimed to evaluate the treatment response, survival profiles, prognostic
factors and adverse events of anlotinib in treating advanced non-small cell lung cancer …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …